GlassScriptPhysician profile
Robert W Petrie
NPI 1700230612
$8,717.80
in general payments reported to CMS, 2019-2025
42 companies · $1,899 in 2025
The $1,899 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $1,074 · 2021: $1,100 · 2022: $1,072 · 2023: $1,493 · 2024: $1,754 · 2025: $1,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,146.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,477.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,058.13 | 2019-2025 | Jardiance |
| Abbvie INC. | $776.49 | 2021-2025 | |
| Pfizer INC. | $634.82 | 2019-2025 | |
| Lilly USA, LLC | $504.27 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $417.37 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $407.07 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $357.27 | 2020-2025 | Veozah, Myrbetriq |
| Amgen INC. | $331.37 | 2020-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $285.15 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $268.37 | 2019-2025 | |
| Dexcom, INC. | $258.78 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $203.06 | 2020-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $185.12 | 2019-2023 | Dificid |
| Allergan, INC. | $177.98 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Petrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.